Revvity Shares Rise 3.4%, Analysts Revise Targets
Revvity Shares Rise 3.4%, Analysts Revise Targets
Anonymous
Key Points
1
Revvity’s dividend carries a 13.33% payout ratio, equating to $0.28 annually and a 0.2% yield; the payment is scheduled for Nov. 13 to shareholders of record on Oct. 23.
2
Revvity’s institutional ownership stands at 86.7%, compared with 69.5% for Cytek Biosciences, while insiders own just 0.9% of Revvity versus 10.4% of Cytek. Revvity also has a lower beta of 1.09 than Cytek’s 1.18, indicating somewhat lower share-price volatility.
3
Across the 10 research-tools and consumables companies reviewed, second-quarter revenue exceeded analysts’ estimates by 1.7% as a group, while guidance for the following quarter was broadly in line with expectations. The sector faces both potential growth from synthetic biology, personalized medicine, laboratory automation and AI, and risks from research-funding cycles, pricing pressure and supply-chain disruptions.
4
Revvity shares were trading at $128.49 after rising 3.4% on Sept. 14, and had gained 55.5% over the prior year within a 52-week range of $81.22 to $133.00. GuruFocus gave the company a GF Score of 77 out of 100, indicating above-average financial health and performance.
Revvity shares climbed 3.4% on September 14, reaching $128.49 as analysts updated their ratings and price targets on the life-sciences tools company. GuruFocus flagged valuation concerns, noting the stock trades 9.4% above its intrinsic value with a price-to-earnings ratio of 61.2—more than double its five-year median of 30.1.
The company reported second-quarter revenue of $711.1 million, up 4.5% year over year, and declared a quarterly dividend of $0.07 per share. Despite the stock's 55.5% gain over the past year, insider selling without offsetting purchases signals caution among company insiders.
Analyst Moves Signal Cautious Optimism
Revvity drew mixed but mostly positive analyst attention. KeyCorp raised its price target to $165, while other analysts assigned neutral and sector-perform ratings. The broader research-tools industry exceeded revenue expectations by 1.7% in the second quarter, suggesting solid underlying demand.
The company's dividend carries a 13.33% payout ratio, equating to $0.28 annually with a 0.2% yield. The payment will be distributed November 13 to shareholders of record on October 23.
Revvity Outperforms Rival Cytek on Most Metrics
Revvity led rival Cytek Biosciences on 10 of 14 comparison measures and boasts larger revenue, earnings and institutional ownership at 86.7%. GuruFocus gave Revvity a GF Score of 77 out of 100, indicating above-average financial health. However, Cytek commands a stronger consensus analyst rating and appears more attractively valued.
Revvity insiders own just 0.9% of shares versus 10.4% for Cytek, suggesting less insider confidence. Revvity also has lower volatility with a beta of 1.09 compared to Cytek's 1.18. Institutional investors account for the bulk of Revvity's shareholder base.
Valuation Risks Overshadow Growth Opportunities
At 61.2 times earnings, Revvity trades at a steep premium to its historical average. GuruFocus estimates the stock is overvalued by 9.4% based on fundamentals. Rising interest rates and earnings pressure could weigh on future gains from this elevated base.
The research-tools sector faces headwinds from research-funding cycles, pricing pressure and supply-chain disruptions. Growth opportunities exist in synthetic biology, personalized medicine, laboratory automation and AI, but these may not offset near-term risks. Insider sales without purchases add to investor caution.
Strong Year Masks Stretched Valuation Metrics
Revvity stock has gained 55.5% over the past year and now trades within a 52-week range of $81.22 to $133.00. This sharp rally has pushed valuations far ahead of historical norms and peer averages. GuruFocus data shows the price-to-earnings ratio has doubled relative to the five-year median.
Investors should weigh the company's solid operational performance against stretched multiples. The combination of insider selling and premium valuations suggests the stock may offer limited upside at current levels, despite analyst confidence in long-term industry trends.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
17
Articles
46
Reach
63
A
AnonymousAuthor
